Discovering a potent small molecule inhibitor for gankyrin using de novo drug design approach

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Gankyrin is an oncoprotein over-expressed in Hepatocellular Carcinoma (HCC).
• Gankyrin plays a crucial role in cell cycle regulation, making it a potential therapeutic target.
• Inhibiting gankyrin could restrict cancer cell growth and promote apoptosis.

Purpose of the Study:

• To design a potent ligand capable of inhibiting gankyrin activity.
• To identify a molecule that can effectively bind to and disrupt gankyrin function for HCC therapy.

Main Methods:

• Utilized a molecular docking approach to design potential drug candidates.
• Screened molecules for optimal fit within the gankyrin protein cavity.
• Evaluated binding affinity and energy of the designed ligand to gankyrin.

Main Results:

• Successfully designed a potent ligand that precisely fits the gankyrin cavity.
• The designed molecule forms numerous close interactions with gankyrin's active site residues.
• The ligand exhibits minimum energy and a strong binding affinity for gankyrin.

Conclusions:

• A novel ligand has been successfully designed to inhibit gankyrin activity.
• This molecule represents a promising therapeutic candidate for targeting gankyrin in Hepatocellular Carcinoma.
• The findings support gankyrin as a viable drug target for cancer treatment.